Immuneering Co. (NASDAQ:IMRX) Receives Consensus Rating of “Hold” from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have been assigned an average recommendation of “Hold” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.80.

Several research firms recently issued reports on IMRX. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Monday, January 13th. Morgan Stanley cut shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Immuneering in a report on Wednesday, January 8th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of Immuneering during the 2nd quarter valued at $492,000. Renaissance Technologies LLC acquired a new stake in Immuneering during the 2nd quarter worth about $447,000. HighTower Advisors LLC lifted its stake in Immuneering by 21.4% in the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after buying an additional 9,400 shares during the period. Tidemark LLC bought a new position in Immuneering during the third quarter worth $129,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering in the 2nd quarter valued at about $44,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Price Performance

Shares of IMRX stock opened at $1.94 on Monday. Immuneering has a 12 month low of $1.00 and a 12 month high of $7.68. The stock has a 50 day moving average of $2.07 and a 200-day moving average of $1.86. The firm has a market cap of $60.24 million, a PE ratio of -0.98 and a beta of -0.36.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.